Research ExplorerPublicationsTotal body irradiation plus fludarabine versus busulfan plus...

Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT

Standard

Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT. / Swoboda, Ryszard; Labopin, Myriam; Giebel, Sebastian; Schroeder, Thomas; Kröger, Nicolaus; Arat, Mutlu; Savani, Bipin; Spyridonidis, Alexandros; Hamladji, Rose-Marie; Potter, Victoria; Berceanu, Ana; Yakoub-Agha, Ibrahim; Rambaldi, Alessandro; Ozdogu, Hakan; Sanz, Jaime; Nagler, Arnon; Mohty, Mohamad.

In: BONE MARROW TRANSPL, Vol. 58, No. 3, 03.2023, p. 282-287.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Swoboda, R, Labopin, M, Giebel, S, Schroeder, T, Kröger, N, Arat, M, Savani, B, Spyridonidis, A, Hamladji, R-M, Potter, V, Berceanu, A, Yakoub-Agha, I, Rambaldi, A, Ozdogu, H, Sanz, J, Nagler, A & Mohty, M 2023, 'Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT', BONE MARROW TRANSPL, vol. 58, no. 3, pp. 282-287. https://doi.org/10.1038/s41409-022-01882-5

APA

Swoboda, R., Labopin, M., Giebel, S., Schroeder, T., Kröger, N., Arat, M., Savani, B., Spyridonidis, A., Hamladji, R-M., Potter, V., Berceanu, A., Yakoub-Agha, I., Rambaldi, A., Ozdogu, H., Sanz, J., Nagler, A., & Mohty, M. (2023). Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT. BONE MARROW TRANSPL, 58(3), 282-287. https://doi.org/10.1038/s41409-022-01882-5

Vancouver

Swoboda R, Labopin M, Giebel S, Schroeder T, Kröger N, Arat M et al. Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT. BONE MARROW TRANSPL. 2023 Mar;58(3):282-287. https://doi.org/10.1038/s41409-022-01882-5

Bibtex

@article{7425192e7f0e418e80bcc0cfdf8afe7c,
title = "Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT",
abstract = "Cyclophosphamide is frequently substituted with fludarabine (Flu) in conditioning regimens before allogeneic hematopoietic cell transplantation (allo-HCT). We aimed to compare retrospectively, total body irradiation (12 Gy) plus Flu (FluTBI12) versus busulfan (Bu) plus Flu (FB4) as a myeloablative conditioning before allo-HCT in patients with acute myeloid leukemia (AML). Out of 3203 patients who met the inclusion criteria, 109 patients treated with FluTBI12 and 213 treated with FB4 were included in a final matched-pair analysis. In both groups, median patient age was 41 years, first or second complete remission (CR1/CR2) proportion was 78%/22%, allo-HCT from an unrelated donor was performed in 78% of patients. The probabilities of leukemia-free survival and overall survival at 2 years in FluTBI12 and FB4 groups were 65% vs. 60% (p = 0.64) and 70% vs. 72% (p = 0.87), respectively. The cumulative incidence of relapse was 19% vs. 29% (p = 0.11), while non-relapse mortality was 16% vs. 11%, respectively (p = 0.13). There were no statistical differences in both acute and chronic graft-versus-host disease (GVHD) incidence. The probability of GVHD-free, relapse-free survival (GRFS) was 49% for both groups. FluTBI12 and FB4 are comparable myeloablative regimens before allo-HCT in AML patients transplanted in CR1 and CR2.",
author = "Ryszard Swoboda and Myriam Labopin and Sebastian Giebel and Thomas Schroeder and Nicolaus Kr{\"o}ger and Mutlu Arat and Bipin Savani and Alexandros Spyridonidis and Rose-Marie Hamladji and Victoria Potter and Ana Berceanu and Ibrahim Yakoub-Agha and Alessandro Rambaldi and Hakan Ozdogu and Jaime Sanz and Arnon Nagler and Mohamad Mohty",
note = "{\textcopyright} 2022. The Author(s), under exclusive licence to Springer Nature Limited.",
year = "2023",
month = mar,
doi = "10.1038/s41409-022-01882-5",
language = "English",
volume = "58",
pages = "282--287",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "3",

}

RIS

TY - JOUR

T1 - Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT

AU - Swoboda, Ryszard

AU - Labopin, Myriam

AU - Giebel, Sebastian

AU - Schroeder, Thomas

AU - Kröger, Nicolaus

AU - Arat, Mutlu

AU - Savani, Bipin

AU - Spyridonidis, Alexandros

AU - Hamladji, Rose-Marie

AU - Potter, Victoria

AU - Berceanu, Ana

AU - Yakoub-Agha, Ibrahim

AU - Rambaldi, Alessandro

AU - Ozdogu, Hakan

AU - Sanz, Jaime

AU - Nagler, Arnon

AU - Mohty, Mohamad

N1 - © 2022. The Author(s), under exclusive licence to Springer Nature Limited.

PY - 2023/3

Y1 - 2023/3

N2 - Cyclophosphamide is frequently substituted with fludarabine (Flu) in conditioning regimens before allogeneic hematopoietic cell transplantation (allo-HCT). We aimed to compare retrospectively, total body irradiation (12 Gy) plus Flu (FluTBI12) versus busulfan (Bu) plus Flu (FB4) as a myeloablative conditioning before allo-HCT in patients with acute myeloid leukemia (AML). Out of 3203 patients who met the inclusion criteria, 109 patients treated with FluTBI12 and 213 treated with FB4 were included in a final matched-pair analysis. In both groups, median patient age was 41 years, first or second complete remission (CR1/CR2) proportion was 78%/22%, allo-HCT from an unrelated donor was performed in 78% of patients. The probabilities of leukemia-free survival and overall survival at 2 years in FluTBI12 and FB4 groups were 65% vs. 60% (p = 0.64) and 70% vs. 72% (p = 0.87), respectively. The cumulative incidence of relapse was 19% vs. 29% (p = 0.11), while non-relapse mortality was 16% vs. 11%, respectively (p = 0.13). There were no statistical differences in both acute and chronic graft-versus-host disease (GVHD) incidence. The probability of GVHD-free, relapse-free survival (GRFS) was 49% for both groups. FluTBI12 and FB4 are comparable myeloablative regimens before allo-HCT in AML patients transplanted in CR1 and CR2.

AB - Cyclophosphamide is frequently substituted with fludarabine (Flu) in conditioning regimens before allogeneic hematopoietic cell transplantation (allo-HCT). We aimed to compare retrospectively, total body irradiation (12 Gy) plus Flu (FluTBI12) versus busulfan (Bu) plus Flu (FB4) as a myeloablative conditioning before allo-HCT in patients with acute myeloid leukemia (AML). Out of 3203 patients who met the inclusion criteria, 109 patients treated with FluTBI12 and 213 treated with FB4 were included in a final matched-pair analysis. In both groups, median patient age was 41 years, first or second complete remission (CR1/CR2) proportion was 78%/22%, allo-HCT from an unrelated donor was performed in 78% of patients. The probabilities of leukemia-free survival and overall survival at 2 years in FluTBI12 and FB4 groups were 65% vs. 60% (p = 0.64) and 70% vs. 72% (p = 0.87), respectively. The cumulative incidence of relapse was 19% vs. 29% (p = 0.11), while non-relapse mortality was 16% vs. 11%, respectively (p = 0.13). There were no statistical differences in both acute and chronic graft-versus-host disease (GVHD) incidence. The probability of GVHD-free, relapse-free survival (GRFS) was 49% for both groups. FluTBI12 and FB4 are comparable myeloablative regimens before allo-HCT in AML patients transplanted in CR1 and CR2.

U2 - 10.1038/s41409-022-01882-5

DO - 10.1038/s41409-022-01882-5

M3 - SCORING: Journal article

C2 - 36460819

VL - 58

SP - 282

EP - 287

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 3

ER -